CN108610312A - 具有改善的治疗指数的硝酰基供体 - Google Patents

具有改善的治疗指数的硝酰基供体 Download PDF

Info

Publication number
CN108610312A
CN108610312A CN201810074807.8A CN201810074807A CN108610312A CN 108610312 A CN108610312 A CN 108610312A CN 201810074807 A CN201810074807 A CN 201810074807A CN 108610312 A CN108610312 A CN 108610312A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutical composition
nitroxyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810074807.8A
Other languages
English (en)
Chinese (zh)
Inventor
文森·杰可·卡利什
费德列克·阿瑟·布鲁克菲尔德
史蒂芬·马汀·考特尼
莉萨·玛莉·弗罗斯特
约翰·P·托斯卡诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardioxyl Pharmaceuticals Inc
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of CN108610312A publication Critical patent/CN108610312A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201810074807.8A 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体 Pending CN108610312A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US61/754,237 2013-01-18
US201361782781P 2013-03-14 2013-03-14
US61/782,781 2013-03-14
CN201480013565.1A CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480013565.1A Division CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体

Publications (1)

Publication Number Publication Date
CN108610312A true CN108610312A (zh) 2018-10-02

Family

ID=50064795

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201480013223.XA Active CN105142627B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物
CN201810074807.8A Pending CN108610312A (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体
CN201910446030.8A Active CN110179777B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物
CN201480013565.1A Active CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201480013223.XA Active CN105142627B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910446030.8A Active CN110179777B (zh) 2013-01-18 2014-01-17 包含硝酰基供体的医药组合物
CN201480013565.1A Active CN105073105B (zh) 2013-01-18 2014-01-17 具有改善的治疗指数的硝酰基供体

Country Status (29)

Country Link
US (13) US8987326B2 (OSRAM)
EP (5) EP3427728B1 (OSRAM)
JP (5) JP6449171B2 (OSRAM)
KR (2) KR102177899B1 (OSRAM)
CN (4) CN105142627B (OSRAM)
AU (5) AU2014207404B2 (OSRAM)
BR (2) BR112015017251B1 (OSRAM)
CA (2) CA2898445C (OSRAM)
CY (3) CY1120535T1 (OSRAM)
DK (3) DK2945621T3 (OSRAM)
ES (4) ES2882279T3 (OSRAM)
HK (1) HK1251170B (OSRAM)
HR (3) HRP20182144T1 (OSRAM)
HU (3) HUE041861T2 (OSRAM)
IL (4) IL239906B (OSRAM)
LT (3) LT2945621T (OSRAM)
MX (2) MX363843B (OSRAM)
NZ (4) NZ709986A (OSRAM)
PL (3) PL3284463T3 (OSRAM)
PT (3) PT3284463T (OSRAM)
RS (3) RS59434B1 (OSRAM)
RU (3) RU2684916C2 (OSRAM)
SG (6) SG11201505568PA (OSRAM)
SI (3) SI3284463T1 (OSRAM)
SM (3) SMT201800088T1 (OSRAM)
TR (1) TR201802211T4 (OSRAM)
TW (3) TWI686193B (OSRAM)
WO (2) WO2014113696A1 (OSRAM)
ZA (2) ZA201505090B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2489350E (pt) 2006-03-17 2014-03-10 Univ Johns Hopkins Med Derivados de n-hidroxilsulfonamida como novos dadores de nitroxilo fisiologicamente úteis
US9181213B2 (en) 2011-10-17 2015-11-10 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as HNO donors
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
US10456405B2 (en) 2015-09-07 2019-10-29 Zhejiang Huahai Pharmaceutical Co., Ltd Nitric oxide-releasing prodrug molecule of substituted quinazolines
EP3365328A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2017070084A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
EP3490975B1 (en) 2016-07-28 2021-05-05 The Johns Hopkins University O-substituted hydroxamic acids
EP3565544A1 (en) 2017-01-03 2019-11-13 Cardioxyl Pharmaceuticals Inc. Method of administering nitroxyl donating compounds
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143950A (zh) * 1994-01-19 1997-02-26 比克荷兰有限公司 含硝酰基的苄胺衍生物及其在治疗心血管疾病和治疗升高眼压中的应用
CN101874018A (zh) * 2007-09-26 2010-10-27 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n-羟基磺酰胺衍生物
CN102076342A (zh) * 2008-05-07 2011-05-25 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
CN102753520A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
CN102753519A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
US6525081B1 (en) 1997-10-24 2003-02-25 Shionogi & Co., Ltd. Antirheumatic
PT930302E (pt) * 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
WO1999063385A1 (en) 1998-06-04 1999-12-09 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000006128A1 (fr) 1998-07-28 2000-02-10 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
ATE330950T1 (de) * 2000-12-13 2006-07-15 Wyeth Corp Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1718621A4 (en) 2004-01-30 2009-08-19 Univ Johns Hopkins NITROXYL PREPARATION COMPOUNDS APPLICATION METHOD
WO2006043965A1 (en) 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CA2613477C (en) 2005-06-23 2013-12-03 Johns Hopkins University Thiol-sensitive positive inotropes
PT2489350E (pt) 2006-03-17 2014-03-10 Univ Johns Hopkins Med Derivados de n-hidroxilsulfonamida como novos dadores de nitroxilo fisiologicamente úteis
EP2010476A4 (en) 2006-04-13 2011-01-26 Univ Wake Forest Health Sciences NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
US9181213B2 (en) 2011-10-17 2015-11-10 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as HNO donors
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143950A (zh) * 1994-01-19 1997-02-26 比克荷兰有限公司 含硝酰基的苄胺衍生物及其在治疗心血管疾病和治疗升高眼压中的应用
CN101874018A (zh) * 2007-09-26 2010-10-27 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n-羟基磺酰胺衍生物
CN102076342A (zh) * 2008-05-07 2011-05-25 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
CN102753520A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
CN102753519A (zh) * 2009-12-07 2012-10-24 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物

Also Published As

Publication number Publication date
BR112015017251A2 (pt) 2017-07-11
SMT201800088T1 (it) 2018-03-08
RU2018143994A (ru) 2019-01-16
CN105142627A (zh) 2015-12-09
PT2945620T (pt) 2018-02-21
DK2945620T3 (en) 2018-02-05
US10792273B2 (en) 2020-10-06
JP6311038B2 (ja) 2018-04-11
WO2014113700A9 (en) 2014-10-09
TW201446242A (zh) 2014-12-16
BR112015017241A2 (pt) 2017-07-11
SG10201802855TA (en) 2018-05-30
US12186301B2 (en) 2025-01-07
TWI619491B (zh) 2018-04-01
IL258882A (en) 2018-06-28
EP3427728B1 (en) 2021-07-07
US20240066002A1 (en) 2024-02-29
AU2014207408A8 (en) 2015-08-27
EP2945620B1 (en) 2017-11-22
JP2016510326A (ja) 2016-04-07
US10245249B2 (en) 2019-04-02
EP3567031A1 (en) 2019-11-13
MX363843B (es) 2019-04-05
JP6656345B2 (ja) 2020-03-04
CN105142627B (zh) 2019-06-21
JP6533159B2 (ja) 2019-06-19
LT3284463T (lt) 2019-11-11
RU2684916C2 (ru) 2019-04-16
AU2018203240B2 (en) 2019-12-12
JP6801045B2 (ja) 2020-12-16
RU2676277C2 (ru) 2018-12-27
PT3284463T (pt) 2019-10-30
US20180235927A1 (en) 2018-08-23
IL239906B (en) 2018-05-31
SMT201900575T1 (it) 2019-11-13
CA2898445A1 (en) 2014-07-24
US11273143B2 (en) 2022-03-15
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
IL239906A0 (en) 2015-08-31
US10548872B2 (en) 2020-02-04
US9586896B2 (en) 2017-03-07
US20190224159A1 (en) 2019-07-25
JP2017125015A (ja) 2017-07-20
TWI686193B (zh) 2020-03-01
KR20150107853A (ko) 2015-09-23
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
RS58174B1 (sr) 2019-03-29
ES2751922T3 (es) 2020-04-02
DK2945621T3 (en) 2019-02-11
JP2019172682A (ja) 2019-10-10
ZA201604798B (en) 2018-01-31
HK1251170B (en) 2020-04-09
TR201802211T4 (tr) 2018-03-21
AU2014207408C1 (en) 2018-09-06
SG10201802862WA (en) 2018-05-30
CN110179777B (zh) 2022-07-15
SG11201505567RA (en) 2015-09-29
JP2019089764A (ja) 2019-06-13
WO2014113700A1 (en) 2014-07-24
EP3427728A1 (en) 2019-01-16
MX2015009276A (es) 2015-10-30
AU2018241168B2 (en) 2020-04-02
SG10201913286PA (en) 2020-02-27
CY1122177T1 (el) 2020-11-25
BR112015017241B1 (pt) 2021-10-26
LT2945620T (lt) 2018-02-12
HK1216858A1 (en) 2016-12-09
PL2945621T3 (pl) 2019-05-31
TWI712409B (zh) 2020-12-11
AU2014207408A1 (en) 2015-08-13
CN110179777A (zh) 2019-08-30
US20210015784A1 (en) 2021-01-21
ES2882279T3 (es) 2021-12-01
CA2898443C (en) 2022-05-31
IL259233A (en) 2018-07-31
CY1121480T1 (el) 2020-05-29
US9968584B2 (en) 2018-05-15
US20150175566A1 (en) 2015-06-25
HUE036589T2 (hu) 2018-07-30
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
MX373176B (es) 2020-04-22
AU2014207408B2 (en) 2018-03-01
US20170151210A1 (en) 2017-06-01
DK3284463T3 (da) 2019-10-28
US20220193026A1 (en) 2022-06-23
HUE046722T2 (hu) 2020-03-30
US20200163929A1 (en) 2020-05-28
RU2015134583A (ru) 2017-02-22
HRP20191919T1 (hr) 2020-01-10
US20140206769A1 (en) 2014-07-24
SI3284463T1 (sl) 2019-12-31
HRP20182144T1 (hr) 2019-03-08
SMT201900027T1 (it) 2019-02-28
CN105073105B (zh) 2018-02-27
AU2014207404A1 (en) 2015-08-13
CA2898445C (en) 2022-05-03
US11786501B2 (en) 2023-10-17
NZ709985A (en) 2020-05-29
HRP20180121T1 (hr) 2018-02-23
TW201442702A (zh) 2014-11-16
SI2945620T1 (en) 2018-01-31
SI2945621T1 (sl) 2019-01-31
BR112015017241A8 (pt) 2019-10-29
US10213408B2 (en) 2019-02-26
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
AU2018241168A1 (en) 2018-11-01
PT2945621T (pt) 2019-01-21
HK1216857A1 (en) 2016-12-09
RS59434B1 (sr) 2019-11-29
US9156804B2 (en) 2015-10-13
NZ748771A (en) 2019-12-20
US20190133990A1 (en) 2019-05-09
EP3284463B1 (en) 2019-07-24
JP2016505044A (ja) 2016-02-18
HUE041861T2 (hu) 2019-06-28
ES2705240T3 (es) 2019-03-22
AU2018203240A1 (en) 2018-05-31
JP6449171B2 (ja) 2019-01-09
CA2898443A1 (en) 2014-07-24
ZA201505090B (en) 2016-10-26
BR112015017251A8 (pt) 2019-10-29
BR112015017251B1 (pt) 2021-10-26
TW201934120A (zh) 2019-09-01
LT2945621T (lt) 2019-01-10
IL239952B (en) 2018-05-31
KR20150108879A (ko) 2015-09-30
NZ709986A (en) 2020-01-31
EP2945620A1 (en) 2015-11-25
IL259233B (en) 2019-10-31
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
PL3284463T3 (pl) 2019-12-31
KR102177899B1 (ko) 2020-11-12
SG10201913441RA (en) 2020-03-30
KR102277165B1 (ko) 2021-07-14
US10517847B2 (en) 2019-12-31
PL2945620T3 (pl) 2018-03-30
CN105073105A (zh) 2015-11-18
WO2014113696A1 (en) 2014-07-24
EP3284463A1 (en) 2018-02-21
NZ748769A (en) 2020-05-29
HRP20191919T8 (hr) 2021-10-01
ES2659969T3 (es) 2018-03-20
US8987326B2 (en) 2015-03-24
AU2017200147B2 (en) 2018-07-05
MX2015009269A (es) 2015-10-30
IL239952A0 (en) 2015-08-31
AU2014207404B2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CN105073105B (zh) 具有改善的治疗指数的硝酰基供体
HK1251170A1 (en) Nitroxyl donors with improved therapeutic index
HK40017499A (en) Nitroxyl donors with improved therapeutic index
HK1216857B (en) Nitroxyl donors with improved therapeutic index

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181002